ACE-inhibitorer er fortsat førstevalg ved behandling af hjertesvigt: en gennemgang af et Cochranereview

Niels Gadsbøll, Christian Torp-Pedersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

A new Cochrane metaanalysis has reviewed the literature on the use of angiotensin receptor blockers (ARB) in patients with heart failure and left ventricular systolic dysfunction. The conclusion supports the present recommendation from the European Society of Cardiology that angiotensin converting enzyme inhibitors (ACE-I) are first choice and that ARBs should be reserved to patients who are intolerant to ACE-Is. Neither ACE-Is nor ARBs are effective in the treatment of heart failure patients with normal left ventricular function.
Bidragets oversatte titelACE inhibitors continue to be first choice in the treatment of heart failure patients
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind175
Udgave nummer22
Sider (fra-til)1566-1568
ISSN0041-5782
StatusUdgivet - 2013
Udgivet eksterntJa

Citationsformater